ValuEngine upgraded shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) from a strong sell rating to a sell rating in a report published on Friday morning.
Several other equities analysts have also commented on BLPH. Zacks Investment Research lowered Bellerophon Therapeutics from a buy rating to a hold rating in a research report on Wednesday, September 6th. HC Wainwright reiterated a buy rating and set a $5.00 price objective on shares of Bellerophon Therapeutics in a research report on Wednesday, September 6th.
Shares of Bellerophon Therapeutics (NASDAQ:BLPH) opened at 1.18 on Friday. Bellerophon Therapeutics has a 52 week low of $0.43 and a 52 week high of $1.98. The firm’s market capitalization is $41.90 million. The stock’s 50 day moving average price is $1.20 and its 200-day moving average price is $1.36.
Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03. Equities analysts predict that Bellerophon Therapeutics will post ($1.12) earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of BLPH. Susquehanna International Group LLP bought a new position in Bellerophon Therapeutics during the 2nd quarter worth approximately $1,316,000. Renaissance Technologies LLC grew its position in Bellerophon Therapeutics by 99.7% during the 1st quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock worth $711,000 after acquiring an additional 238,300 shares during the last quarter. Vanguard Group Inc. grew its position in Bellerophon Therapeutics by 52.6% during the 2nd quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock worth $821,000 after acquiring an additional 211,111 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new position in Bellerophon Therapeutics during the 1st quarter worth approximately $125,000. Institutional investors and hedge funds own 45.85% of the company’s stock.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.